Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

By
Natalia Fernández-Díaz
María Mateos-González
Ana Pertejo-Fernández
Juan Diego Cacho-Lavín
María José Juan-Fita
Isabel Chirivella-González
Mikel Arruti-Ibarbia
Ovidio Fernández-Calvo
Natalia Fernández-Núñez
María José Méndez-Vidal
Martín Lázaro-Quintela
Aurea Molina-Díaz
Nieves Del Pozo-Alonso
Olatz Etxaniz-Ulazia
Silvia Margarita García-Acuña
Yoel Z. Betancor
Ainara Azueta-Etxebarria
Ana Calatrava-Fons
Helena Lombardía-Rodríguez
Lorena Alarcón-Molero
Leire Etxegarai-Ganboa
Abraham Antón-Cameselle
José Antonio Bello-Giz
Carlos Manuel Neira-De Paz
Teresa Cabaleiro
Teresa González-Serrano
José Antonio Ortiz-Rey
Felipe Sacristán-Lista
Silvia García-Rubín
Elisa Ortega
Cristina Carrato-Moñino
Santiago Aguín-Losada
Luis León-Mateos
Jorge García-González
Álvaro Pinto-Marín
Ignacio Duran
Rafael López-López
Urbano Anido-Herranz
Juan Ruiz-Bañobre
November 28, 2025

Bmc Cancer

Objective:

To evaluate the efficacy of nivolumab in advanced renal cell carcinoma (aRCC) patients treated in routine clinical practice and assess the impact of pre-treatment factors on treatment outcomes.

Approach:

Key Findings:

Median age of patients was 65 years; 27% were female and 73% male.
90% of patients had an ECOG-PS score of 0 or 1.
Clear cell renal cell carcinoma was the predominant subtype (85%).
Nivolumab demonstrated a significant overall survival benefit in the real-world setting.

Interpretation:

The study confirms the efficacy of nivolumab in aRCC patients in routine clinical practice, aligning with findings from controlled clinical trials.

Limitations:

Retrospective design may introduce selection bias.
Limited generalizability due to the specific patient population and treatment settings.

Conclusion:

Nivolumab is effective in advanced renal cell carcinoma patients treated in routine clinical practice, with outcomes consistent with clinical trial data.

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

Related Content

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC